This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
25I-NBOMe: Difference between revisions
>Pharmreduction m no source |
>JohntheCaptain mNo edit summary |
||
| (36 intermediate revisions by 9 users not shown) | |||
| Line 4: | Line 4: | ||
{{SubstanceBox/25I-NBOMe}} | {{SubstanceBox/25I-NBOMe}} | ||
'''25I-NBOMe''' (also known as '''2C-I-NBOMe''', '''NBOMe-2C-I''', '''Cimbi-5''' and '''N-Bomb''') is a novel [[Psychoactive class::psychedelic]] substance of the [[chemical class::phenethylamine]] chemical class that produces an array of visually-dominant and stimulating [[psychedelic]] effects when [[Routes of administration|administered]]. | '''25I-NBOMe''' (also known as '''2C-I-NBOMe''', '''NBOMe-2C-I''', '''Cimbi-5''', '''Smiles''', and one of many drugs referred to as '''N-Bomb''') is a novel [[Psychoactive class::psychedelic]] substance of the [[chemical class::phenethylamine]] chemical class that produces an array of visually-dominant and stimulating [[psychedelic]] effects when [[Routes of administration|administered]]. | ||
The name 25I-NBOMe, which short-hand for 2C-I-NBOMe, is a derivative of the phenethylamine psychedelic [[2C-I]]. It was first synthesized and documented in 2003 by Ralf Heim at the Free University of Berlin.<ref name="Ralf Heim PhD. (2010-02-28)"> | The name 25I-NBOMe, which short-hand for 2C-I-NBOMe, is a derivative of the phenethylamine psychedelic [[2C-I]]. It was first synthesized and documented in 2003 by Ralf Heim at the Free University of Berlin.<ref name="Ralf Heim PhD. (2010-02-28)">{{cite journal | vauthors=((Heim, R.)) | title=Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2 -Methoxybenzyl-Partialstruktur: Entwicklung eines neuen Struktur-Wirkungskonzepts | date= 2004 | url=https://refubium.fu-berlin.de/handle/fub188/11995 | doi=10.17169/refubium-16193 | access-date=10 May 2013}}</ref> It was further researched by a team at Purdue University led by [[David E. Nichols|David Nichols]].<ref name="Michael Robert Braden PhD. (2007)">{{cite journal | vauthors=((Braden, M. R.)) | journal=Theses and Dissertations Available from ProQuest | title=Towards a biophysical understanding of hallucinogen action | pages=1–176 | date=1 January 2007 | url=http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 | access-date=8 August 2012}} | ||
</ref> It has been studied in its 11C radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET).<ref name="Ettrup2011">{{cite journal | vauthors=((Ettrup, A.)), ((Hansen, M.)), ((Santini, M. A.)), ((Paine, J.)), ((Gillings, N.)), ((Palner, M.)), ((Lehel, S.)), ((Herth, M. M.)), ((Madsen, J.)), ((Kristensen, J.)), ((Begtrup, M.)), ((Knudsen, G. M.)) | journal=European Journal of Nuclear Medicine and Molecular Imaging | title=Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers | volume=38 | issue=4 | pages=681–693 | date= April 2011 | issn=1619-7089 | doi=10.1007/s00259-010-1686-8}}</ref><ref>{{cite book | vauthors=((Hansen, M.)) | date= 2010 | title=Design and synthesis of selective serotonin receptor agonists for positron emission tomography imaging of the brain: PhD thesis | publisher=Faculty of Pharmaceutical Sciences, University of Copenhagen | isbn=9788792719003}}</ref> | |||
It is worth noting that compounds of the [[25x-NBOMe|NBOMe]] family should be administered [[sublingual|sublingually]] by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes. | It is worth noting that compounds of the [[25x-NBOMe|NBOMe]] family (any of which could be referred to as "N-Bomb", especially 25I-NBOMe and [[25N-NBOMe]]) should be administered [[sublingual|sublingually]] by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes. | ||
Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25I-NBOMe in humans. It had no history of human use before being sold online as a [[designer drug]] in 2010.{{citation needed}}. It has been associated with many deaths and hospitalizations. Anecdotal reports suggest that this substance may be difficult to use safely due to its highly sensitive dose-response and unpredictable effects. | Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25I-NBOMe in humans. It had no history of human use before being sold online as a [[designer drug]] in 2010.{{citation needed}}. It has been associated with many deaths and hospitalizations. Anecdotal reports suggest that this substance may be difficult to use safely due to its highly sensitive dose-response and unpredictable effects. | ||
| Line 17: | Line 18: | ||
==Pharmacology== | ==Pharmacology== | ||
{{Further|Serotonergic psychedelic}} | {{Further|Serotonergic psychedelic}} | ||
25I-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] where it acts as | 25I-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] where it acts as a Full [[Agonist#Agonists|agonist]].<ref name="Ettrup2011" /> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive. | ||
Among psychedelics, this compound is considered to be pharmacologically unique in terms of the high potency, affinity, and selectivity with which it binds to the 5-HT2a receptor.<ref name=" | Among psychedelics, this compound is considered to be pharmacologically unique in terms of the high potency, affinity, and selectivity with which it binds to the 5-HT2a receptor.<ref name="Ettrup2011" /> Contrary to popular belief, it is not a "full agonist"{{citation needed}}, although questions have been raised about how the effects it produces differ from other 5-HT2a partial agonists, which include the range of traditional psychedelics. | ||
The Ki values of the following targets were greater than 500 Ki: 5-HT1A, D3, H2, 5-HT1D, α1A adrenergic, δ opioid, serotonin reuptake transporter, 5-HT5A, 5-HT1B, D2, 5-HT7, D1, 5-HT3, 5-HT1E, D5, muscarinic M1-M5, H3, and the dopamine reuptake transporter.<ref name="high specific">High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand | The Ki values of the following targets were greater than 500 Ki: 5-HT1A, D3, H2, 5-HT1D, α1A adrenergic, δ opioid, serotonin reuptake transporter, 5-HT5A, 5-HT1B, D2, 5-HT7, D1, 5-HT3, 5-HT1E, D5, muscarinic M1-M5, H3, and the dopamine reuptake transporter.<ref name="high specific">{{cite journal | vauthors=((Nichols, D. E.)), ((Frescas, S. P.)), ((Chemel, B. R.)), ((Rehder, K. S.)), ((Zhong, D.)), ((Lewin, A. H.)) | journal=Bioorganic & Medicinal Chemistry | title=High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand | volume=16 | issue=11 | pages=6116–6123 | date=1 June 2008 | issn=1464-3391 | doi=10.1016/j.bmc.2008.04.050}}</ref> | ||
{| class="wikitable sortable" style="text-align: right; margin-left: 10px;" | {| class="wikitable sortable" style="text-align: right; margin-left: 10px;" | ||
|+Ki-values<ref | |+Ki-values<ref name="Ettrup2011" /><ref name="high specific" /> | ||
! scope="col" |Receptor||Ki (nM)|| class="unsortable" |± | ! scope="col" |Receptor||Ki (nM)|| class="unsortable" |± | ||
| Line 51: | Line 52: | ||
==Subjective effects== | ==Subjective effects== | ||
{{Preamble/SubjectiveEffects}} | {{Preamble/SubjectiveEffects}} | ||
{{effects/base | {{effects/base | ||
| Line 78: | Line 80: | ||
*'''[[Effect::Pupil dilation]]''' | *'''[[Effect::Pupil dilation]]''' | ||
*'''[[Effect::Headaches]]''' | *'''[[Effect::Headaches]]''' | ||
*'''[[Effect::Seizures]]''' | *'''[[Effect::Seizures]]'''- This effect is far more common in doses exceeding a heavy dose and may manifest as status epilepticus wherein seizures last more than 5 minutes or do not stop without medical intervention | ||
*'''[[Effect::Rhabdomyolysis]]''' | |||
}} | }} | ||
| Line 148: | Line 151: | ||
*'''[[Effect::Time distortion]]''' | *'''[[Effect::Time distortion]]''' | ||
*'''[[Effect::Wakefulness]]''' | *'''[[Effect::Wakefulness]]''' | ||
*'''[[Effect::HPPD]]''' | |||
}} | }} | ||
| Line 182: | Line 186: | ||
'''Short-term as well as long-term damage of NBOMes have been occasionally tied to serious physical and mental problems on seemingly random people, including memory and speech difficulties, heart problems, HPPD and in some cases Anxiety and PTSD, from particularly difficult experiences.''' | '''Short-term as well as long-term damage of NBOMes have been occasionally tied to serious physical and mental problems on seemingly random people, including memory and speech difficulties, heart problems, HPPD and in some cases Anxiety and PTSD, from particularly difficult experiences.''' | ||
25I-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The [[LD50|LD<sub>50</sub>]] has not yet been determined although it is [[Toxicity::potentially fatal at heavy dosages]].<ref> | 25I-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The [[LD50|LD<sub>50</sub>]] has not yet been determined although it is [[Toxicity::potentially fatal at heavy dosages]].<ref name="25Ifatal">{{Citation | title=Erowid 25I-NBOMe (2C-I-NBOMe) Vault : Fatalities / Deaths | url=https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml}}</ref> [[PsychonautWiki]] advises that due to 25I-NBOMe's extreme potency it should not be insufflated as this method of administration appears to have led to several deaths in the past year. | ||
This substance came to media attention in early 2012 after a cluster of seven non-fatal [[overdose]]s with the drug were reported in or around Richmond, Virginia.<ref name="Kids overdosing on new drug"> | This substance came to media attention in early 2012 after a cluster of seven non-fatal [[overdose]]s with the drug were reported in or around Richmond, Virginia.<ref name="Kids overdosing on new drug">{{Citation | vauthors=((Geller, L.)) | year=2012 | title=Kids overdosing on new drug | publisher=WWBT NBC12 | url=https://www.nbc12.com/story/16964534/kids-overdosing-on-new-drug}}</ref><ref name="New street drug"> New street drug causing concern among medics. Vanessa Araiza, WBRC, Feb 28, 2012, | http://www.wsfa.com/story/16977573/new-street-drug-causing-concern-among-medics</ref> As of May 2013, 25I-NBOMe has reportedly led to five overdose deaths in the United States.<ref><nowiki>{{Citation | title=New drug N-bomb hits the street, terrifying parents, troubling cops | url=</nowiki>https://www.nydailynews.com/news/national/new-synthetic-hallucinogen-n-bomb-killing-users-cops-article-1.1336327</ref> In June 2012, two teens in Grand Forks, North Dakota and East Grand Forks, Minnesota fatally overdosed on a substance that was allegedly 25I-NBOMe, resulting in lengthy sentences for two of the parties involved and a Federal indictment against the Texas-based online vendor.<ref> Breaking Bad: Digital Drug Sales, Analog Drug Deaths. Craig Malisow, Houston Press, March 13, 2013 | http://www.houstonpress.com/2013-03-14/news/motion-research-charles-carlton/</ref> | ||
A 21-year-old man from Little Rock, Arkansas died in October 2012 after taking a liquid drop of the drug nasally at a music festival. He was reported to have consumed caffeinated alcoholic beverages for "several hours" beforehand. It is unclear what other drugs he may have consumed, as autopsies usually do not test for the presence of research chemicals.<ref name="21 yr old dies"> 21-year-old dies after one drop of new synthetic drug at Voodoo Fest | A 21-year-old man from Little Rock, Arkansas died in October 2012 after taking a liquid drop of the drug nasally at a music festival. He was reported to have consumed caffeinated alcoholic beverages for "several hours" beforehand. It is unclear what other drugs he may have consumed, as autopsies usually do not test for the presence of research chemicals.<ref name="21 yr old dies">{{Citation | vauthors=((Martin, N.)) | year=2012 | title=21-year-old dies after one drop of new synthetic drug at Voodoo Fest | publisher=NOLA | url=https://www.nola.com/news/crime_police/article_526a4b28-8e79-5b4c-8310-637c946b616c.html}}</ref> | ||
A man in Australia died from injuries sustained by running into trees and power poles while intoxicated by 25I-NBOMe.<ref name="Australia death"> New hallucinogenic drug 25B-NBOMe and 25I-NBOMe led to South Australian man's bizarre death | http://www.adelaidenow.com.au/news/south-australia/new-hallucinogenic-drug-25b-nbome-and-25i-nbome-led-to-south-australian-mans-bizarre-death/story-e6frea83-1226472672220/</ref> | A man in Australia died from injuries sustained by running into trees and power poles while intoxicated by 25I-NBOMe.<ref name="Australia death"> New hallucinogenic drug 25B-NBOMe and 25I-NBOMe led to South Australian man's bizarre death | http://www.adelaidenow.com.au/news/south-australia/new-hallucinogenic-drug-25b-nbome-and-25i-nbome-led-to-south-australian-mans-bizarre-death/story-e6frea83-1226472672220/</ref> | ||
| Line 212: | Line 216: | ||
In September 2014, the European Council decided that 25I-NBOMe shall be subjected by the Member States to control measures and criminal penalties by October 2, 2015.<ref>{{cite web|url=https://op.europa.eu/o/opportal-service/download-handler?identifier=025bb164-4937-11e4-a0cb-01aa75ed71a1&format=pdfa1a&language=en&productionSystem=cellar&part=|title=Council Implementing Decision on subjecting 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures|date=September 25, 2014|publication-date=October 1, 2014|work=Official Journal of the European Union|pages=22-26|id=L 287|publisher=Office for Official Publications of the European Communites|oclc=52224955}}</ref> | In September 2014, the European Council decided that 25I-NBOMe shall be subjected by the Member States to control measures and criminal penalties by October 2, 2015.<ref>{{cite web|url=https://op.europa.eu/o/opportal-service/download-handler?identifier=025bb164-4937-11e4-a0cb-01aa75ed71a1&format=pdfa1a&language=en&productionSystem=cellar&part=|title=Council Implementing Decision on subjecting 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures|date=September 25, 2014|publication-date=October 1, 2014|work=Official Journal of the European Union|pages=22-26|id=L 287|publisher=Office for Official Publications of the European Communites|oclc=52224955}}</ref> | ||
*'''Australia''': Possession, production and sale is illegal. | *'''Australia''': Possession, production and sale is illegal.<ref>https://web.archive.org/web/20160602092257/https://www.legislation.gov.au/Details/F2015L01534/Html/Text#_Toc420496379</ref> | ||
*'''Austria''': Since June 26, 2019, 25I-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)<ref>https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig</ref> | *'''Austria''': Since June 26, 2019, 25I-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)<ref>https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig</ref> | ||
*'''Brazil''': Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref> | *'''Brazil''': Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref> | ||
*'''Canada''': 25I-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.<ref>Controlled Drugs and Substances Act | *'''Canada''': 25I-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.<ref>{{Citation | vauthors=((Branch, L. S.)) | year=2022 | title=Consolidated federal laws of Canada, Controlled Drugs and Substances Act | url=https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html}}</ref> | ||
*'''China''': As of October 2015 25I-NBOMe is a controlled substance in China.<ref>http://www.sfda.gov.cn/WS01/CL0056/130753.html | 关于印发《非药用类麻醉药品和精神药品列管办法》的通知 </ref> | *'''China''': As of October 2015 25I-NBOMe is a controlled substance in China.<ref>http://www.sfda.gov.cn/WS01/CL0056/130753.html | 关于印发《非药用类麻醉药品和精神药品列管办法》的通知 </ref> | ||
*'''Denmark''': 25I-NBOMe is controlled by the generic classification of phenethylamines in the Executive Order on Euphoriant Substances.<ref name="EMCDDA">{{cite web|url=http://www.emcdda.europa.eu/system/files/publications/817/TDAS14003ENN_466654.pdf|title=25I-NBOMe: EMCDDA–Europol Joint Report on a new psychoactive substance: 25I-NBOMe (4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine)|publisher=European Monitoring Centre for Drugs and Drug Addiction|access-date=February 18, 2020|issn=1977-7868|year=2014|isbn=978-92-9168-682-7|doi=10.2810/27828}}</ref> | *'''Denmark''': 25I-NBOMe is controlled by the generic classification of phenethylamines in the Executive Order on Euphoriant Substances.<ref name="EMCDDA">{{cite web|url=http://www.emcdda.europa.eu/system/files/publications/817/TDAS14003ENN_466654.pdf|title=25I-NBOMe: EMCDDA–Europol Joint Report on a new psychoactive substance: 25I-NBOMe (4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine)|publisher=European Monitoring Centre for Drugs and Drug Addiction|access-date=February 18, 2020|issn=1977-7868|year=2014|isbn=978-92-9168-682-7|doi=10.2810/27828}}</ref> | ||
| Line 223: | Line 227: | ||
*'''Israel''': The drug was banned in 2012.<ref>http://www.health.gov.il/LegislationLibrary/25574413.pdf</ref> | *'''Israel''': The drug was banned in 2012.<ref>http://www.health.gov.il/LegislationLibrary/25574413.pdf</ref> | ||
*'''Italy''': In Italy 25I-NBOMe is a Schedule 1 controlled substance, meaning it's illegal in this state.<ref>Tabella 1 Stupefacenti dello Stato Italiano |http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf</ref> | *'''Italy''': In Italy 25I-NBOMe is a Schedule 1 controlled substance, meaning it's illegal in this state.<ref>Tabella 1 Stupefacenti dello Stato Italiano |http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf</ref> | ||
*'''Latvia''': 25I-NBOMe is a Schedule I controlled substance.<ref>Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem | *'''Japan''': 25I-NBOMe is a narcotic drug in Japan effective November 1st, 2015.<ref>{{Citation | title=新たに４物質を麻薬に指定し、規制の強化を図ります ｜報道発表資料｜厚生労働省 | publisher=厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)] | url=https://www.mhlw.go.jp/stf/houdou/0000098723.html}}</ref> | ||
*'''New Zealand''': 25I-NBOMe is a Schedule 2 controlled substance in New Zealand.<ref> | *'''Latvia''': 25I-NBOMe is a Schedule I controlled substance.<ref>{{Citation | title=Zaudējis spēku - Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem | url=https://likumi.lv/doc.php?id=121086}}</ref> | ||
*'''The Netherlands:''' 25I-NBOMe is classified as a Lijst 1 (List 1) controlled substance under the Opiumwet (Opium Law). <ref>https://wetten.overheid.nl/BWBR0001941/2024-04-16#BijlageI</ref> | |||
*'''New Zealand''': 25I-NBOMe is a Schedule 2 controlled substance in New Zealand.<ref>{{Citation | title=Misuse of Drugs Act 1975 No 116 (as at 07 December 2021), Public Act – New Zealand Legislation | url=https://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html}}</ref> | |||
*'''Norway''': 25I-NBOMe is controlled by the generic scheduling of phenethylamines as of February 14, 2013.<ref name="EMCDDA"></ref> | *'''Norway''': 25I-NBOMe is controlled by the generic scheduling of phenethylamines as of February 14, 2013.<ref name="EMCDDA"></ref> | ||
*'''Poland''': 25I-NBOMe falls under the definition of a ‘substitution drug’ under the Act on Counteracting Drug Addiction and the Act on State Sanitary Inspection, 2010. As such its marketing and production is penalised with a fine (administrative sanctions).<ref name="EMCDDA"></ref> | *'''Poland''': 25I-NBOMe falls under the definition of a ‘substitution drug’ under the Act on Counteracting Drug Addiction and the Act on State Sanitary Inspection, 2010. As such its marketing and production is penalised with a fine (administrative sanctions).<ref name="EMCDDA"></ref> | ||
*'''Romania''': In 2011, Romania banned all psychoactive substances,<ref> | *'''Romania''': In 2011, Romania banned all psychoactive substances,<ref>{{Citation | vauthors=((Takács, I. G.)) | year=2013 | title=Colored City: Recreational drug use in Belgrade | url=https://drogriporter.hu/en/node2329/}}</ref> no matter what they really are.<ref>http://www.dreptonline.ro/legislatie/legea_194_2011_comba</ref> | ||
*'''Russia''': Possession, production and sale is illegal.{{citation needed}} | *'''Russia''': Possession, production and sale is illegal.{{citation needed}} | ||
*'''Slovenia''': 25I-NBOMe was included in a Decree amending the classification of illicit drugs (Official Gazette of RS No. 62/2013).<ref name="EMCDDA"></ref> | *'''Slovenia''': 25I-NBOMe was included in a Decree amending the classification of illicit drugs (Official Gazette of RS No. 62/2013).<ref name="EMCDDA"></ref> | ||
*'''Sweden''': 25I-NBOMe is classed as Schedule I.<ref>Läkemedelsverkets författningssamling | *'''Sweden''': 25I-NBOMe is classed as Schedule I.<ref>{{Citation | title=Läkemedelsverkets författningssamling | url=http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf}}</ref> | ||
*'''Switzerland''': 25I-NBOMe is a controlled substance specifically named under Verzeichnis D.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | *'''Switzerland''': 25I-NBOMe is a controlled substance specifically named under Verzeichnis D.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | ||
*'''United Kingdom''': 25I-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.<ref> | *'''United Kingdom''': 25I-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.<ref>{{Citation | title=The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014 | url=https://www.legislation.gov.uk/uksi/2014/1106/made}}</ref> | ||
*'''United States''': On Nov 15, 2013, the DEA added 25I-NBOMe to Schedule I using their emergency scheduling powers, making it "temporarily" in Schedule I for 2 years.<ref>http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml</ref> | *'''United States''': On Nov 15, 2013, the DEA added 25I-NBOMe to Schedule I using their emergency scheduling powers, making it "temporarily" in Schedule I for 2 years.<ref>http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml</ref> | ||
| Line 250: | Line 256: | ||
*[https://erowid.org/chemicals/2ci_nbome/2ci_nbome.shtml 25I-NBOMe (Erowid Vault)] | *[https://erowid.org/chemicals/2ci_nbome/2ci_nbome.shtml 25I-NBOMe (Erowid Vault)] | ||
*[https://isomerdesign.com/PiHKAL/explore.php?id=5380 25I-NBOMe (Isomer Design)] | *[https://isomerdesign.com/PiHKAL/explore.php?id=5380 25I-NBOMe (Isomer Design)] | ||
*[https://drugs-forum.com/wiki/25I-NBOMe 25I-NBOMe (Drugs-Forum)] | |||
===Discussion=== | ===Discussion=== | ||